|
| Name | Company | Agent(s) | Description | Comment |
|
| Physical barrier |
|
| Remoxy [24] | Pain therapeutics and King Pharmaceuticals | Oxycodone extended release | Hard gelatin capsule containing viscous liquid | ORADUR technology (extended-release formulation) |
| Acuracet [25] | Acura | Oxycodone immediate release and acetaminophen | Impediments to snorting and injection (not further described) | |
| Vycavert [26] | Hydrocodone immediate release and acetaminophen | Impediments to snorting and injection (not further described) | |
| C0L-003 [27] | Collegium pharmaceutical | Oxycodone sustained release | Multiparticulate matrix with particles in waxy excipient base | |
| COL-172 [27] | Oxycodone sustained release | Multiparticulate matrix with particles in waxy excipient base | |
| ReXista [28] | Intellipharmaceutics | Oxycodone sustained release | Not described | |
| OxyContin [29] | Purdue | Oxycodone controlled release | Resists crushing and dissolving | |
| TQ-1015 [30] | | Oxycodone extended release | Crush and tamper resistant | Securel technology |
| TQ-1017 [31] | TheraQuest Biosciences | Tramadol extended release | Transforms into viscous substance when hydrated | |
| TQ1020 [32] | | Levorphanol extended release | Not stated | |
| DDS-08B [33] | Labopharm/Paladin | Oxycodone/APAP extended release | Extended release even if tablet is tampered with | |
| Exalgo [34] | Neuromed/Covidien | Hydromorphone extended release | Osmotic delivery system (OROS push-pull technology) | New formulation |
| Not named [35] | Pisgah Labs | Hydrocodone | Insoluble at pH ranges in mucosal membranes | |
| ADPREM [36, 37] | Egalet (Denmark) | Morphine | Erodible matrix covered by water-impermeable nonerodible shell | |
| Egalet hydrocodone [36] | Egalet (Denmark) | Hydrocone | Hard matrix | |
|
| Agonist/Antagonist |
|
| Embeda [38] | King Pharmaceuticals | Morphine/naltrexone | Pellets of morphine surrounding a hard core of sequestered naltrexone | Naltrexone pellets are 1.0 to 1.7 mm diameter |
| ALO-01 [39] | Alpharma | Morphine extended release with naltrexone | Sequestered naltrexone | |
| Oxytrex [40] | Albert Einstein College of Medicine | Oxycodone and ultra-low-dose naltrexone | Ultra-low-dose naltrexone | |
| OxyNal or ELI-216 [40] | Elite Pharmaceuticals | Oxycodone-controlled release with naltrexone pellets | Pellets release naltrexone only when crushed | |
| Talwin [41] | Sanofi-Aventis | Pentazocine and naloxone | Naloxone | Naloxone released if drug administered parenterally |
| Suboxone Film [42] | Reckitt Benckiser | Buprenorphine/naloxone | Naloxone | |
|
| Aversive agents |
|
| Acurox with niacin [43] | Acura Pharmaceuticals and King Pharmaceuticals | Oxycodone immediate release 5 and 7.5 mg | Niacin; tablets contain a gel-forming ingredient | |
|
| Prodrug |
|
| NRP 290 [44, 45] | New River Pharmaceuticals | Conditional bioreversible derivative of hydrocodone | Lysine-modified prodrug | NRP 369 is backup for NRP 290 |
|
